The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Initial results from a first-in-human phase 1 study of LY4170156, an ADC targeting folate receptor alpha (FRa), in advanced ovarian cancer and other solid tumors.
 
Isabelle Ray-Coquard
Honoraria - Abbvie; Advaxis; AGENUS; Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; DECIPHERA; Genmab; GlaxoSmithKline; IMMUNOCORE; Immunogen; Macrogenics; MERSANA; MSD Oncology; Novartis; OxOnc; Pfizer; PharmaMar; PMV Pharma; Roche; Seagen; Sutro Biopharma; Tesaro
Consulting or Advisory Role - Abbvie; AGENUS; AstraZeneca; Blueprint Medicines; BMS; Bristol-Myers Squibb; Clovis Oncology; Corcept Therapeutics; Daichi; Deciphera; Eisai; Genmab; GlaxoSmithKline; Immunocore; Immunogen; Incyte; Macrogenics; Mersana; MSD Oncology; Netris Pharma; Novartis; Novocure; Ose pharma; Pfizer; PharmaMar; Roche; Scorpion Therapeutics; Seagen; seagen; Sutro Biopharma; Tesaro
Research Funding - BMS; MSD Oncology; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Advaxis; AstraZeneca; BMS; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro
(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; Belgium health authorities; French National Cancer Institute (INCA); GERMAN health authorities; ITALIAN HEALTH AUTORITIES
 
David O'Malley
Consulting or Advisory Role - Abbvie; AstraZeneca; Corcept Therapeutics; DualityBio; GlaxoSmithKline; GOG Foundation; Merck; Novocure; Novocure; Pfizer; Regeneron; Sutro Biopharma; Verastem; Zentalis
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie/Stemcentrx (Inst); Acerta Pharma (Inst); Advaxis (Inst); Ajinomoto (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BBI Healthcare (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Ergomed (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Immunogen (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); NovoCure (Inst); OncoQuest (Inst); Pfizer (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Therapeutics (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); SeaGen (Inst); Seagen (Inst); Sumitomo Dainippon Pharma Oncology, Inc. (Inst); Sutro Biopharma (Inst); Tesaro (Inst); Verastem (Inst); Zentalis (Inst)
 
Bhavana Pothuri
Consulting or Advisory Role - AstraZeneca; BioNTech; Daiichi Sankyo; Gillead Sciences; GlaxoSmithKline; GOG Foundation; Immunogen; Incyte; Karyopharm Therapeutics; Loxo/Lilly; Merck; Mersana; Onconova Therapeutics; OnCusp Therapeutics; R-Pharm; Regeneron; Seagen; Signatera
Research Funding - Acrivon Therapeutics (Inst); Agenus (Inst); AstraZeneca (Inst); Celsion (Inst); Daiichi Sankyo (Inst); DualityBio (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Mersana (Inst); Mural (Inst); NRG Oncology (Inst); Onconova Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Sutro Biopharma (Inst); Toray Industries (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - BioNTech; GlaxoSmithKline; GOG Foundation; Merck
Other Relationship - Society of Gynecologic Oncology
 
Ana Oaknin
Consulting or Advisory Role - Abbvie; AGENUS; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo; Debiopharm Group; Deciphera; Eisai; Exelixis; Genmab; GlaxoSmithKline; Immunogen; ITeos Therapeutics; Merck Sharp & Dohme; Mersana; Myriad Genetics; Novocure; OncoXerna Therapeutics; PharmaMar; Regeneron; Roche; Seagen / Pfizer; Shattuck Labs; Sutro Biopharma; TORL Therapuetics; Zentalis; Zymeworks
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; Immunogen; MSD; Roche
Research Funding - Abbvie (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); PharmaMar (Inst); Regeneron (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche
 
Nehal Lakhani
Research Funding - Alexo Therapeutics (Inst); Alkermes (Inst); Alkermes/Mural Oncology (Inst); Alpine Immune Sciences (Inst); Alpine Immune Sciences (Inst); Apexian Pharmaceuticals (Inst); Arcus Ventures (Inst); Artios (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech SE (Inst); Biosplice (Inst); Celgene (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Epizyme (Inst); Forty Seven (Inst); Genmab (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Janssen (Inst); Jounce Therapeutics (Inst); KSQ Therapeutics (Inst); LAM Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Northern Biologics (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Quanta Therapeutics (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Sapience Therapeutics (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Servier (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)
 
Takafumi Koyama
Honoraria - AstraZeneca; Chugai Pharma; Sysmex
Consulting or Advisory Role - Amgen
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo RD Novare (Inst); Janssen (Inst); Lilly (Inst); Novartis (Inst); PACT Pharma (Inst); Pfizer (Inst); Takeda (Inst); Zymeworks (Inst)
 
Shigehisa Kitano
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Janssen; Lilly Japan; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; GlaxoSmithKline; ImmuniT Research Inc.; Kyowa Kirin; Ono Pharmaceutical; Rakuten Medical; Sumitomo Dainippon Pharma; United Immunity
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kyowa Kirin; Loxo/Lilly (Inst); Merck KGaA; MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takara Bio (Inst); Takeda (Inst)
 
William McKean
No Relationships to Disclose
 
Ainhoa Madariaga
Honoraria - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD; Pharma&
Consulting or Advisory Role - Abbvie; AstraZeneca; Eisai; GlaxoSmithKline; PharmaMar
Research Funding - Kyowa Kirin International
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; MSD
 
Meena Okera
Consulting or Advisory Role - AstraZeneca; Lilly
Speakers' Bureau - AstraZeneca
Research Funding - multiple (Inst)
Travel, Accommodations, Expenses - MSD Oncology
 
Myong Cheol Lim
No Relationships to Disclose
 
Jose Perez-Fidalgo
Consulting or Advisory Role - Abbvie; AstraZeneca; Clovis Oncology; Deciphera; Eisai; GlaxoSmithKline; Karyopharm Therapeutics; MSD; Pharmaand; Regeneron
Speakers' Bureau - AstraZeneca Spain; Clovis Oncology; Eisai; GlaxoSmithKline; MSD Oncology; PharmaMar; Seagen
Research Funding - AstraZeneca Spain (Inst); GlaxoSmithKline (Inst); Pharmamar (Inst)
Patents, Royalties, Other Intellectual Property - Pending patent
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - AstraZeneca Spain; Novartis
 
Giuseppe Curigliano
Leadership - ESMO; ESMO; ESMO Open; European Society of Breast Cancer Specialists (EUSOMA=
Honoraria - Ellipses Pharma
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celcuity; Daichi-Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; GlaxoSmithKline; Guardant Health; Hengrui Therapeutics; Lilly; Menarini; Merck; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen; Veracyte
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daichii Sankyo; Pfizer; Roche/Genentech
 
Domenica Lorusso
No Relationships to Disclose
 
Ramez Eskander
Consulting or Advisory Role - AbbVie; AstraZeneca/MedImmune; BioNTech SE; Daiichi Sankyo/Lilly; Eisai; Gilead Sciences; GlaxoSmithKline; Immunogen; Merck; Myriad Genetics; Pfizer; PMV Pharma; Regeneron; Seagen
Research Funding - Acrivon Therapeutics (Inst); AstraZeneca (Inst); Corcept Therapeutics (Inst); Daiichi Sankyo/Astra Zeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst); Nivectis (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Eisai; Merck
Other Relationship - GOG Foundation
 
Shannon Westin
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Clovis Oncology; Curio Science; Daiichi Sankyo; Eisai; EQRX; Genentech; Gerson Lehrman Group; Gilead Sciences; GlaxoSmithKline; Immunocore; Immunogen; Incyte; Lilly; Loxo/Lilly; Medscape; Merck; Mereo BioPharma; Mersana; Mersana; NGM Biopharmaceuticals; Nuvectis Pharma; Nuvectis Pharma; OncLive; pharma&; Roche; Seagen; Targeted Oncology; Verastem; Vincerx Pharma; Zentalis; ZielBio
Research Funding - AstraZeneca (Inst); Avenge Bio (Inst); Bayer (Inst); Bio-Path Holdings, Inc (Inst); Clovis Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Jazz Pharmaceuticals (Inst); Loxo/Lilly (Inst); Mereo BioPharma (Inst); Novartis (Inst); Nuvectis Pharma (Inst); Pfizer (Inst); Roche/Genentech (Inst); Zentalis (Inst)
 
Umut Ozbek
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Marine Manvelyan
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Emin Avsar
Employment - Bristol Myers and Squibb; Lilly; Novartis Institutes for BioMedical Research
Stock and Other Ownership Interests - Bristol MyersSquibb; GlaxoSmithKline; Lilly; Seelos Therapeutics
 
Claire Friedman
Honoraria - GlaxoSmithKline; MJH Healthcare Holdings, LLC
Consulting or Advisory Role - AADi; Arch Oncology; Bristol Myers Squibb; Loxo/Lilly
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Genentech (Inst); Hotspot Therapeutics (Inst); Immunocore (Inst); Loxo/Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Seagen (Inst); Volastra Therapeutics (Inst)
Travel, Accommodations, Expenses - Puma Biotechnology
(OPTIONAL) Uncompensated Relationships - Genentech; Marengo Therapeutics; Merck